Luis Antonio Díaz

机构：Pontificia Universidad Católica de Chile, UC San Diego Health System, University of California San Diego, Global Health Council, University of California San Diego Medical Center, Nanomaterials and Nanotechnology Research Center · ORCID：0000-0002-8540-4930

发表论文 220 篇 · 总被引 12497 次 · h-index 33

代表论文

• Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes (2025 · JAMA Network Open · 被引 10)
• Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 9)
• Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD ) (2025 · Alimentary Pharmacology & Therapeutics · 被引 9)
• Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings (2025 · Clinical and Molecular Hepatology · 被引 3)
• Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply (2025 · Alimentary Pharmacology & Therapeutics · 被引 2)
• Progression of FIB-4 index predicts major adverse cardiovascular events in patients with metabolic dysfunction (2025 · Gastroenterología y Hepatología · 被引 2)